| Citation: |
ZHOU Shi. Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(6): 552-556. DOI: 10.3971/j.issn.1000-8578.2022.21.1370
|
Primary hepatocellular carcinoma (HCC) is the sixth most common malignant tumor in the world, and ranks third in tumor-related deaths. The incidence and mortality of HCC in China are among the top five in both men and women, and are increasing year by year, while less than 30% of patients can be surgically resected. With the continuous development of medical technology, interventional therapy has played a key role in the treatment of HCC. This article reviews the latest progress of interventional therapy such as transarterial chemoembolization, transarterial radioembolization, radiofrequency ablation and microwave ablation, as well as interventional therapy combined with molecular targeted therapy and immunotherapy.
| [1] |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. doi: 10.1016/S0140-6736(18)30010-2
|
| [2] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
|
| [3] |
Wu JY, Yin ZY, Bai YN, et al. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study[J]. J Hepatocell Carcinoma, 2021, 8: 1233-1240. doi: 10.2147/JHC.S332420
|
| [4] |
Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase Ⅲ Trial[J]. J Clin Oncol, 2020, 38(3): 193-202. doi: 10.1200/JCO.19.01307
|
| [5] |
中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J]. 肿瘤防治研究, 2022, 49(3): 251-276. doi: 10.3971/j.issn.1000-8578.2022.03.0001
National Health Commission of the People's Republic of China. Standardization for diagnosis and treatment of primary hepatic carcinoma (2022 Edition)[J]. Zhong Liu Fang Zhi Yan Jiu, 2022, 49(3): 251-276. doi: 10.3971/j.issn.1000-8578.2022.03.0001
|
| [6] |
Galle PR, Tovoli F, Foerster F, et al. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy[J]. J Hepatol, 2017, 67(1): 173-183. doi: 10.1016/j.jhep.2017.03.007
|
| [7] |
Wang TC, An TZ, Li JX, et al. Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma[J]. Front Mol Biosci, 2021, 8: 633590. doi: 10.3389/fmolb.2021.633590
|
| [8] |
Finn R, Ikeda M, Zhu A, et al. LBO09-A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma[J]. J Hepatol, 2020, 73(Suppl1): S120-S121.
|
| [9] |
Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art[J]. World J Gastroenterol, 2018, 24(2): 161-169. doi: 10.3748/wjg.v24.i2.161
|
| [10] |
Lee EW, Khan S. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma[J]. Clin Mol Hepatol, 2017, 23(4): 265-272. doi: 10.3350/cmh.2017.0111
|
| [11] |
Shi Q, Chen D, Zhou C, et al. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study[J]. Cancer Manag Res, 2020, 12: 5461-5468. doi: 10.2147/CMAR.S255960
|
| [12] |
Shen L, Zhang Y, Guo Y, et al. 987P A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC)[J]. Ann Oncol, 2020, 31: S690-S691.
|
| [13] |
He M, Li Q, Zou R, et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs. Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5(7): 953-960. doi: 10.1001/jamaoncol.2019.0250
|
| [14] |
He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83. doi: 10.1186/s40880-017-0251-2
|
| [15] |
Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations[J]. J Hepatol, 2018, 68(4): 783-797. doi: 10.1016/j.jhep.2017.10.004
|
| [16] |
Hocquelet A, Aubé C, Rode A, et al. Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC[J]. J Hepatol, 2017, 66(1): 67-74. doi: 10.1016/j.jhep.2016.07.010
|
| [17] |
English K, Brodin NP, Shankar V, et al. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization with Survival Rates in Patients with Hepatocellular Carcinoma[J]. JAMA Netw Open, 2020, 3(11): e2023942. doi: 10.1001/jamanetworkopen.2020.23942
|
| [18] |
Shi F, Wu M, Lian SS, et al. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes[J]. Radiology, 2019, 293(3): 707-715. doi: 10.1148/radiol.2019181991
|
| [19] |
Yuan H, Liu F, Li X, et al. Angio-CT-Guided Transarterial Chemoembolization Immediately in Combination with Radiofrequency Ablation for Large Hepatocellular Carcinoma[J]. Acad Radiol, 2019, 26(2): 224-231. doi: 10.1016/j.acra.2018.04.007
|
| [20] |
Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis[J]. Onco Targets Ther, 2019, 12: 6407-6438. doi: 10.2147/OTT.S204340
|
| [21] |
杨立新, 赵天慧, 魏强, 等. 超声引导微波消融联合TACE治疗晚期原发性肝癌的疗效及对免疫功能的影响[J]. 中国超声医学杂志, 2020, 36(5): 428-432. doi: 10.3969/j.issn.1002-0101.2020.05.013
Yang LX, Zhao TH, Wei Q, et al. Curative Effect of Ultrasonic Guided Microwave Ablation Combined with TACE in the Treatment of Advanced Primary Liver Cancer and Its Influence on Immune Function[J]. Zhongguo Chao Sheng Yi Xue Za Zhi, 2020, 36(5): 428-432. doi: 10.3969/j.issn.1002-0101.2020.05.013
|
| [22] |
Hu H, Chen GF, Yuan W, et al. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis[J]. Int J Hyperthermia, 2018, 34(8): 1351-1358. doi: 10.1080/02656736.2018.1462536
|
| [23] |
Kim R, Kang TW, Cha DI, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications[J]. Eur Radiol, 2019, 29(2): 654-662. doi: 10.1007/s00330-018-5617-6
|
| [24] |
Sutter O, Calvo J, N'Kontchou G, et al. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series[J]. Radiology, 2017, 284(3): 877-886. doi: 10.1148/radiol.2017161413
|
| [25] |
Kudo M, Ueshima K, Ikeda M, et al. Randomized, open label, multicenter, phase Ⅱ trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial[J]. J Clin Oncol, 2018, 36(4_suppl): 206. doi: 10.1200/JCO.2018.36.4_suppl.206
|
| [26] |
Lu J, Guo JH, Zhu HD, et al. Safety and Efficacy of Irradiation Stent Placement for Malignant Portal Vein Thrombus Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience[J]. J Vasc Interv Radiol, 2017, 28(6): 786-794. doi: 10.1016/j.jvir.2017.02.014
|
| [27] |
Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa[J]. Nat Rev Clin Oncol, 2018, 15(5): 310-324. doi: 10.1038/nrclinonc.2018.9
|
| [28] |
Zhu K, Huang J, Lai L, et al. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation[J]. Radiology, 2018, 288(1): 300-307. doi: 10.1148/radiol.2018172028
|
| [29] |
Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE[J]. Liver Cancer, 2019, 8(5): 299-311. doi: 10.1159/000502905
|
| [30] |
Liu J, Xie S, Duan X, et al. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2020, 85(1): 69-76. doi: 10.1007/s00280-019-04004-z
|
| [31] |
Pinato DJ, Murray SM, Forner A, et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy[J]. J Immunother Cancer, 2021, 9(9): e003311. doi: 10.1136/jitc-2021-003311
|
| [32] |
Gerbes A, Zoulim F, Tilg H, et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma[J]. Gut, 2018, 67(2): 380-388. doi: 10.1136/gutjnl-2017-315068
|
| [33] |
Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545-551. doi: 10.1016/j.jhep.2016.10.029
|
| [34] |
Huang Y, Kim BYS, Chan CK, et al. Improving immune-vascular crosstalk for cancer immunotherapy[J]. Nat Rev Immunol, 2018, 18(3): 195-203. doi: 10.1038/nri.2017.145
|
| [35] |
Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. doi: 10.1200/JCO.20.00808
|
| [36] |
Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma-a strategy to increase resectability[J]. Ann Surg Oncol, 2007, 14(12): 3301-3309. doi: 10.1245/s10434-007-9549-7
|
| [37] |
Tabone M, Calvo A, Russolillo N, et al. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience[J]. J Gastrointest Oncol, 2020, 11(1): 84-90. doi: 10.21037/jgo.2019.06.01
|
| 1. |
黄先涛，赵丽娟，王晨宇，赵婧帆，靖超，汤学勤. 某三级综合医院住院患者恶性肿瘤伴心血管疾病的流行病学特征分析——以河北北方学院附属第一医院为例. 河北北方学院学报(自然科学版). 2025(02): 55-57+63 .
| |
| 2. |
黄玉，石印青，武英材，陈斐. 化疗联合靶向治疗对乳腺癌患者心脏毒性的研究. 山西大同大学学报(自然科学版). 2024(05): 80-84 .
| |
| 3. |
周威，梁冰，宛蕾，李莉，陈岩勤，傅强，张晓燕. 以“疾-患”为中心的药学综合设计性实验教学模式的探索. 药学教育. 2023(01): 75-79 .
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: